Abel Hall LLC’s Terns Pharmaceuticals TERN Stock Holding History

Abel Hall LLC’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,278	Closed	-$436K	–	1074
2026 Q1	$436K	Buy	8,278 +1,883	+29%	+$77.3K	0.09%	241
2025 Q4	$258K	Buy	+6,395	New	+$148K	0.06%	412

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Abel Hall LLC's TERN Position: Q2 2026 in Review

Abel Hall LLC sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 8,278 shares — an estimated $436K sold.

Abel Hall LLC first reported a position in TERN in Q4 2025 and held it in 2 quarters. The position peaked at $436K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Abel Hall LLC reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Abel Hall LLC sold 8,278 Terns Pharmaceuticals shares in Q2 2026, an estimated $436K.
Abel Hall LLC first reported a position in Terns Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Abel Hall LLC's Terns Pharmaceuticals position peaked at $436K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.